- Home
- TARS vs BHC Comparison
TARS vs BHC Comparison
Compare TARS & BHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TARS | BHC |
|---|---|---|
| Founded | 2016 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.1B |
| IPO Year | 2020 | 1996 |
Fundamental Metrics
Financial Performance| Metric | TARS | BHC |
|---|---|---|
| Price | $80.87 | $8.35 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 10 | 7 |
| Target Price | ★ $103.44 | $8.40 |
| AVG Volume (30 Days) | 830.6K | ★ 3.9M |
| Earning Date | 11-03-2026 | 10-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 48.21 | ★ 423.08 |
| EPS | N/A | ★ N/A |
| Revenue | $451,360,000.00 | ★ $8,724,000,000.00 |
| Revenue This Year | $64.28 | $7.43 |
| Revenue Next Year | $26.15 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 146.71 | N/A |
| 52 Week Low | $53.89 | $4.33 |
| 52 Week High | $91.53 | $9.04 |
Technical Indicators
Market Signals| Indicator | TARS | BHC |
|---|---|---|
| Relative Strength Index (RSI) | 64.07 | 65.87 |
| Support Level | $67.49 | $7.86 |
| Resistance Level | $91.53 | N/A |
| Average True Range (ATR) | 3.87 | 0.43 |
| MACD | 1.03 | 0.03 |
| Stochastic Oscillator | 98.27 | 74.42 |
Price Performance
Historical ComparisonAbout TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
About BHC Bausch Health Companies Inc.
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum of its revenue from the Bausch + Lomb segment.